Molecule intelOpportunity: LowerEssential

Daclatasvir

62 brands · 34 companies · product forms

ATC: J05AP07

Opportunity snapshot

Launch attractiveness
27
Market saturation
82
Price room
53
Regulatory risk
0
62
brands
34
companies
Rs 8,009.97
median price
84
price points
3.13x
price spread
100
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 5%

Price room

Across observed sources and strengths
CheapestRs 4,324.4
MedianRs 8,009.97
Most expensiveRs 13,533.95
Spread3.13×
Sources: DRAP-official, DVAGO, Servaid

max/min price ratio 3.13x across 84 trusted points (Rs 4324.4-13533.95). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 12 live products for Daclatasvir — each links to its own medicine page.

Why this score

Launch attractiveness

40% supply-gap(25) + 25% price-variation(53) + 20% low-competition(18) + 15% supply-disruption(0), damped by confidence(100). Higher = more attractive, less crowded opportunity.

Market saturation

34 canonical companies and 62 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 3.13x across 84 trusted points (Rs 4324.4-13533.95). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

No DRAP alerts on this molecule's brands.

Confidence

Full coverage.

Packaged brief for this lower opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.